We are pleased to launch a new CDK (cyclin-dependent kinases) Cell-based Assay Panel for kinase researchers who are focusing on the CDK family.
The CDK Assay Panel consists of 23 CDK targets, and is based on the NanoBRET™ TE technology. Your compound’s direct engagement with each CDK is quantitatively measured inside living HEK293 cells, providing a snapshot of its selectivity across all of the CDK targets in the panel. These assays are performed as single point concentrations in duplicate.This extensive, 23-strong CDK Assay Panel provides:
- Data from a uniform assay format allowing comparison across the CDKs
- Co-expression with a relevant cyclin subunit
- Analysis in a cellular environment providing physiologically relevant data
Special Launch Offers!
(valid for orders placed by September 15th, 2022)
- Buy One Get One Free!
Send in one compouund for analysis, and we will analyse a second compound (sent in the same order) for free! - 20% Off Follow up IC50s!
Subsequent to your CDK Panel data, we are offering a 20% discount (off list price) on IC50s against CDKs in the panel for either or both of your compounds.
If you’re interested in our CDK Panel, and in taking advantage of these limited-time special offers, email us from here.
Further news
-
Newsletter
Cancer treatments using inhibitors of CDK, a cell cycle regulator
Carna Newsletter Vol.16
-
Newsletter
ALK drug resistant mutations: Challenges for the treatment of lung cancer
Carna Newsletter Vol.15
-
Offers
2023 Year-End Campaign
We’ve got good news for you: a special discount for human Kinases from Carna Biosciences.